Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ZhenGe Biotech Completes $51 Million A Round for CDMO Operations

publication date: Apr 1, 2020

Shanghai ZhenGe Biotech, a China CDMO, completed a $51 million Series A financing round led by Shanghai-based healthcare investment firm Lyfe Capital. The company will use the proceeds for additional hires and to expand its Shanghai R&D center, build a GMP production base in the Shanghai Pilot Free Trade Zone (a production facility for macromolecular drugs, growth media and ADC drugs), and expand its US lab. Also participating in the A round were IDG Capital, Cowin Capital, Korea Investment Partners, GT Capital and Shanghai International Group. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here